Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy

Aim: to identify clinical and laboratory biomarkers that determine the nature of the course of myopic choroidal neovascularization (mCNV) and the response to anti-VEGF therapy in women.Material and methods. A prospective non-randomized study was conducted in 52 patients (52 eyes) with active mCNV, t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. V. Grigorieva, T. N. Iureva, Ju. V. Kursakova, E. I. Ivanova, D. Yu. Samsonov, I. M. Mikhalevich
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2021
Materias:	biomarkers myopic choroidal neovascularization hormone disorders Science Q
Acceso en línea:	https://doaj.org/article/f101c9313cff4abba37b61f0b3b69dda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f101c9313cff4abba37b61f0b3b69dda
record_format	dspace
spelling	oai:doaj.org-article:f101c9313cff4abba37b61f0b3b69dda2021-11-23T06:14:45ZBiomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy2541-94202587-959610.29413/ABS.2021-6.2.12https://doaj.org/article/f101c9313cff4abba37b61f0b3b69dda2021-06-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/2737https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Aim: to identify clinical and laboratory biomarkers that determine the nature of the course of myopic choroidal neovascularization (mCNV) and the response to anti-VEGF therapy in women.Material and methods. A prospective non-randomized study was conducted in 52 patients (52 eyes) with active mCNV, treated with ranibizumab intravitreally, 0.5mg. After 12months, the suppression of CNV activity, the number of injections and the fellow eye inclusion in the pathological process were taken into account. There were 2 groups: with a favorable clinical course (n = 31, age – 33,0 ± 5,1 years, anterior-posterior axis (APA) 28,5 ± 0,3 mm) and an unfavorable clinical course (n = 21, age – 34,0 ± 4,1 years, APA – 29,01 ± 0,1 mm). Structural retinal changes, choroid thickness, retinal blood flow, and heart rate were evaluated using OCT and OCTA protocols (Optovue XR Avanti, USA). Studies were conducted before the start of therapy and then one time per month. The concentration of sex and pituitary hormones (ELISA analyzer “Immunohem-2100”), lipoprotein A, Apo B/Apo A (Accent 200 Cormay, Poland), coagulogram data (Helena C-2, UK), and the concentration of highly sensitive C-reactive protein in blood serum before the start of antiangiogenic therapy were studied once.Results. In the first group, 1.4 ± 0.7 ranibizumab injections were administered to suppress the CNV activity. In the opposite group – 3.5 ± 2.1 injections, in 73.7 % of cases, relapses were diagnosed, in 3 cases – primary CNV in the fellow eye. Clinical and laboratory biomarkers of the unfavorable clinical course of mCNV were identified: extreme choroidal thinning, highly organized membranes of a large area, dome-shaped deformation of the posterior pole, excess of the reference values of lipoprotein A, fibrinogen and highly sensitive C-reactive protein by two or more times, an imbalance of sex and pituitary hormones (excess of the reference values of prolactin, follicle stimulating hormone, cortisol, progesterone concentration decrease), a predominant change in the menstrual-ovarian cycle according to the type of amenorrhea and opsomenorrhea.Conclusion. Myopic CNV biomarkers in women allow predicting the response to anti-VEGF therapy, the formation of relapses and the inclusion of the fellow eye in the pathological process.A. V. GrigorievaT. N. IurevaJu. V. KursakovaE. I. IvanovaD. Yu. SamsonovI. M. MikhalevichScientific Сentre for Family Health and Human Reproduction Problemsarticlebiomarkersmyopic choroidal neovascularizationhormone disordersScienceQRUActa Biomedica Scientifica, Vol 6, Iss 2, Pp 105-113 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	biomarkers myopic choroidal neovascularization hormone disorders Science Q
spellingShingle	biomarkers myopic choroidal neovascularization hormone disorders Science Q A. V. Grigorieva T. N. Iureva Ju. V. Kursakova E. I. Ivanova D. Yu. Samsonov I. M. Mikhalevich Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
description	Aim: to identify clinical and laboratory biomarkers that determine the nature of the course of myopic choroidal neovascularization (mCNV) and the response to anti-VEGF therapy in women.Material and methods. A prospective non-randomized study was conducted in 52 patients (52 eyes) with active mCNV, treated with ranibizumab intravitreally, 0.5mg. After 12months, the suppression of CNV activity, the number of injections and the fellow eye inclusion in the pathological process were taken into account. There were 2 groups: with a favorable clinical course (n = 31, age – 33,0 ± 5,1 years, anterior-posterior axis (APA) 28,5 ± 0,3 mm) and an unfavorable clinical course (n = 21, age – 34,0 ± 4,1 years, APA – 29,01 ± 0,1 mm). Structural retinal changes, choroid thickness, retinal blood flow, and heart rate were evaluated using OCT and OCTA protocols (Optovue XR Avanti, USA). Studies were conducted before the start of therapy and then one time per month. The concentration of sex and pituitary hormones (ELISA analyzer “Immunohem-2100”), lipoprotein A, Apo B/Apo A (Accent 200 Cormay, Poland), coagulogram data (Helena C-2, UK), and the concentration of highly sensitive C-reactive protein in blood serum before the start of antiangiogenic therapy were studied once.Results. In the first group, 1.4 ± 0.7 ranibizumab injections were administered to suppress the CNV activity. In the opposite group – 3.5 ± 2.1 injections, in 73.7 % of cases, relapses were diagnosed, in 3 cases – primary CNV in the fellow eye. Clinical and laboratory biomarkers of the unfavorable clinical course of mCNV were identified: extreme choroidal thinning, highly organized membranes of a large area, dome-shaped deformation of the posterior pole, excess of the reference values of lipoprotein A, fibrinogen and highly sensitive C-reactive protein by two or more times, an imbalance of sex and pituitary hormones (excess of the reference values of prolactin, follicle stimulating hormone, cortisol, progesterone concentration decrease), a predominant change in the menstrual-ovarian cycle according to the type of amenorrhea and opsomenorrhea.Conclusion. Myopic CNV biomarkers in women allow predicting the response to anti-VEGF therapy, the formation of relapses and the inclusion of the fellow eye in the pathological process.
format	article
author	A. V. Grigorieva T. N. Iureva Ju. V. Kursakova E. I. Ivanova D. Yu. Samsonov I. M. Mikhalevich
author_facet	A. V. Grigorieva T. N. Iureva Ju. V. Kursakova E. I. Ivanova D. Yu. Samsonov I. M. Mikhalevich
author_sort	A. V. Grigorieva
title	Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
title_short	Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
title_full	Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
title_fullStr	Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
title_full_unstemmed	Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
title_sort	biomarkers of myopic choroidal neovascularization in women, determining the clinical course and response to anti-vegf therapy
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2021
url	https://doaj.org/article/f101c9313cff4abba37b61f0b3b69dda
work_keys_str_mv	AT avgrigorieva biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy AT tniureva biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy AT juvkursakova biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy AT eiivanova biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy AT dyusamsonov biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy AT immikhalevich biomarkersofmyopicchoroidalneovascularizationinwomendeterminingtheclinicalcourseandresponsetoantivegftherapy
_version_	1718416918769041408

Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy

Ejemplares similares